Stay updated with breaking news from Thomas Biegi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Malte Peters
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, fol...
DGAP-News: MorphoSys AG / Key word(s): Half Year Results MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results ...
DGAP-News: MorphoSys AG / Key word(s): Half Year Results MorphoSys AG: Invitation to MorphoSys Second Quarter and First Half Year 202...
Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million)Update of